Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations

被引:124
|
作者
Gourh, Pravitt [1 ]
Arnett, Frank C. [1 ]
Assassi, Shervin [1 ]
Tan, Filemon K. [1 ]
Huang, Mei [1 ]
Diekman, Laura [1 ]
Mayes, Maureen D. [1 ]
Reveille, John D. [1 ]
Agarwal, Sandeep K. [1 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Rheumatol & Clin Immunogenet, Houston, TX 77030 USA
关键词
SOLUBLE IL-6 RECEPTOR; NECROSIS-FACTOR-ALPHA; T-LYMPHOCYTES; SERUM-LEVELS; INTERLEUKIN-6; IL-6; GAMMA LEVELS; ONCOSTATIN M; SCLERODERMA; CELLS; DISEASE;
D O I
10.1186/ar2821
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Systemic sclerosis (SSc) (scleroderma) is a complex autoimmune disease that clinically manifests as progressive fibrosis of the skin and internal organs. Anti-centromere antibodies (ACAs), anti-topoisomerase antibodies (ATAs), and anti-RNA polymerase III antibodies (ARAs) are three mutually exclusive SSc-associated autoantibodies that correlate with distinct clinical subsets characterized by extent of cutaneous involvement and pattern of organ involvement. The current report sought to determine whether plasma cytokine profiles differ in SSc patients grouped according to these SSc-associated autoantibody subsets. Methods Plasma from 444 SSc patients and 216 healthy controls was obtained from the Scleroderma Family Registry and University of Texas Rheumatology Division. Patients were classified according to the presence of ACAs, ATAs, ARAs, or none of the above (antibody-negative). Levels of 13 cytokines were determined using multiplex assays. Results Compared with females, healthy control males had higher plasma levels of IL-2 (P = 0.008), IL-5 (P = 0.01) and IL-8 (P = 0.01). In addition, in controls, IL-6 (P = 0.02) and IL-17 (P = 0.01) levels increased with advancing age. After adjusting for age and gender, SSc patients had higher circulating levels of TNF alpha (P < 0.0001), IL-6 (P < 0.0001), and IFN gamma (P = 0.05) and lower IL-17 (P = 0.0005) and IL-23 (P = 0.014). Additional analyses demonstrated that disease duration also influenced these cytokine profiles. IL-6 was elevated in ATA-positive and ARA-positive patients, but not in ACA-positive patients. IL-8 was uniquely increased in the ATA-positive subset while both ATA-positive and ACA-positive subsets had elevated IFN gamma and IL-10. IL-5 was only significantly increased in the ACA-positive subset. Lastly, patients with interstitial lung disease had elevated IL- 6 and patients with pulmonary hypertension had elevated IL- 6 and IL-13. Conclusions Plasma cytokine profiles differ in SSc patients based on the presence of SSc-associated autoantibodies. Plasma cytokine profiles in SSc patients may also be affected by disease duration and the pattern of internal organ involvement.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans
    Tager, RE
    Tikly, M
    RHEUMATOLOGY, 1999, 38 (05) : 397 - 400
  • [42] Esophagus involvement in systemic sclerosis: ultrasound parameters and association with clinical manifestations
    Ma, Li
    Zhu, Qingli
    Zhang, Yan
    Li, Jianchu
    Jiang, Yuxin
    Xu, Dong
    Zeng, Xiaofeng
    Hou, Yong
    Liu, He
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [43] Systemic Sclerosis in Canada's North American Native Population: Assessment of Clinical and Serological Manifestations
    Bacher, Adrienne
    Mittoo, Shikha
    Hudson, Marie
    Tatibouet, Solene
    Baron, Murray
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (07) : 1121 - 1126
  • [44] Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine
    Benfaremo, Devis
    Agarbati, Silvia
    Mozzicafreddo, Matteo
    Paolini, Chiara
    Svegliati, Silvia
    Moroncini, Gianluca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [45] Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival
    Fernandez-Codina, Andreu
    Pilar Simeon-Aznar, Carmen
    Pinal-Fernandez, Iago
    Rodriguez-Palomares, Jose
    Nazarena Pizzi, Maria
    Eve Hidalgo, Cristina
    Guillen Del Castillo, Alfredo
    Javier Prado-Galbarro, Francisco
    Sarria-Santamera, Antonio
    Fonollosa-Pla, Vicent
    Vilardell-Tarres, Miquel
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (01) : 75 - 84
  • [46] Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort
    Sujau, Ibrahim
    Ng, Chin Teck
    Sthaneshwar, Pavai
    Sockalingam, Sargunan
    Cheah, Tien Eang
    Yahya, Fariz
    Jasmin, Raja
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2015, 18 (04) : 459 - 465
  • [47] Systemic Sclerosis: Elevated Levels of Leukotrienes in Saliva and Plasma Are Associated with Vascular Manifestations and Nailfold Capillaroscopic Abnormalities
    Mandujano, Angelica
    Mendez-Ramirez, Ignacio
    Silveira-Torre, Luis Humberto
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (20)
  • [48] Systemic therapy with calcitonin has positive clinical effects on systemic sclerosis in patients with cutaneous manifestations
    Uslu, Ugur
    Streiff, Laura
    Sticherling, Michael
    EUROPEAN JOURNAL OF DERMATOLOGY, 2018, 28 (03) : 364 - 369
  • [49] Clinical Associations of Degos-Like Lesions in Patients With Systemic Sclerosis
    Song, Paula
    Li, Shufeng
    Lewis, Matthew A.
    Fiorentino, David F.
    Chung, Lorinda
    JAMA DERMATOLOGY, 2023, 159 (03) : 308 - 313
  • [50] Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles
    Carbone, L. D.
    Warrington, K. J.
    Barrow, K. D.
    Pugazhenthi, M.
    Watsky, M. A.
    Somes, G.
    Ingels, J.
    Postlethwaite, A. E.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 146 (03) : 371 - 380